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A B S T R A C T
Background: b-Blockers are used to control heart rate (HR) in patients with atrial ﬁbrillation (AF).
However, the appropriate dosage and efﬁcacy of carvedilol in Japanese AF patients are yet to be clariﬁed.
Methods: In this multicenter, randomized, double-blind study, Japanese patients with persistent or
permanent AF received carvedilol for 6 weeks in the following three dosage-regimen groups: 5-mg ﬁxed-
dose (n = 42), 10-mg dose-escalation (n = 42), or 20-mg dose-escalation (n = 43). To evaluate the efﬁcacy
of each dosage regimen and the dose–response relationship, changes in 24-h mean HR (mHR) on Holter
electrocardiograms from baseline to weeks 2, 4, and 6 were determined as primary endpoints. The effects
on circadian changes in HR, the proportion of patients achieving target HR, clinical symptoms, and
adverse events were also examined.
Results: After 2 weeks, carvedilol 5 mg decreased 24-h mHR signiﬁcantly [6.6 (95% CI: 5.2–8.0) beats/
min, p < 0.0001]. After 6 weeks, carvedilol showed a trend of dose-dependent HR reduction (p = 0.0638):
7.6 (5.4–9.8) in the 5-mg ﬁxed-dose group; 8.9 (6.7–11.1) in the 10-mg dose-escalation group; and 10.6
(8.4–12.8) beats/min in the 20-mg dose-escalation group. There were no serious adverse events related
to carvedilol.
Conclusions: In Japanese patients with persistent or permanent AF, carvedilol at 5 mg once daily
demonstrated a signiﬁcant HR reduction, and step-wise dose escalation from 5 mg to 20 mg showed a
trend of dose-dependent HR reduction.
 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese College of Cardiology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Several large-scale clinical trials conducted in and outside Japan
have shown the importance of heart rate (HR) control as well as
rhythm control in the treatment of atrial ﬁbrillation (AF) [1–4].
b-Blockers, which reduce HR and also provide myocardial
protection or improvement of the prognosis, are recommended* Corresponding author at: Saiseikai Toyama Hospital, 33-1 Kusunoki, Toyama-
shi, Toyama 931-8533, Japan. Tel.: +81 76 437 1111; fax: +81 76 437 1122.
E-mail address: h-inoue@saiseikai-toyama.jp (H. Inoue).
1 Current address: Division of Cardiology, Saiseikai Kumamoto Hospital,
Kumamoto, Japan.
http://dx.doi.org/10.1016/j.jjcc.2016.05.012
0914-5087/ 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese College
creativecommons.org/licenses/by-nc-nd/4.0/).as a rate control drug by both international and Japanese
guidelines for the management of patients with AF [5–7]. In
particular, in both the American guidelines and the European
guidelines, carvedilol is described as one of the ﬁrst-line b-
blockers for rate control [6,7]. Moreover, according to a question-
naire survey involving 1200 Japanese cardiovascular physicians, b-
blockers were the drugs chosen most frequently for the treatment
of AF without heart failure (approximately 53% of physicians), and
among b-blockers, carvedilol was selected most often (approxi-
mately 32% of physicians) [8].
Carvedilol is a non-selective b-blocker with peripheral vasodi-
latory activity, and reduces HR by blocking b1-adrenoceptors.
Carvedilol is approved for treatment of hypertension, angina
pectoris, and chronic heart failure, but not for AF in Japan. In of Cardiology. This is an open access article under the CC BY-NC-ND license (http://
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patients with AF have not yet been established. Thus, the present
study was conducted to evaluate the effects of HR control with
carvedilol at different doses, with the aim of determining the
appropriate dosage and the efﬁcacy of carvedilol in Japanese
patients with AF.
Methods
Patients
This study enrolled patients who fulﬁlled the following criteria:
outpatients aged 20 years with persistent or permanent AF; 24-h
mean HR (mHR) >80 beats per minute (bpm) on Holter
electrocardiogram (ECG); and provision of written informed
consent. The study excluded patients who had received b-blockers,
calcium channel blockers (diltiazem and verapamil), or antiar-
rhythmic drugs; or had been treated for heart failure (New York
Heart Association, NYHA, class II–IV) (for detailed exclusion
criteria, see Supplementary Table 1).
Holter ECG measurement
The sampling rate of Holter ECG was 125 Hz. Analysis of ECG
signals was done by a qualiﬁed technician using analysis software
with monitoring ECG waveform. Errors in R-wave detection and
QRS labeling generated by software automatic analysis were
manually corrected by this technician.Table 1
Baseline patient characteristics.
All patients 5
ﬁxed-d
N 125 42
Age 68.4  9.0a 68
Male 91 (72.8)b 29
Body weight (kg) 66.7  14.6 66
Body mass index (kg/m2) 25.4  4.2 25
Type of atrial ﬁbrillation 
Persistent 34 (27.2) 13
Permanent 91 (72.8) 29
Previous rate control with b-blocker within 6 months 17 (13.6) 6
Baseline blood pressure
Systolic (mmHg) 130  13 129
Diastolic (mmHg) 81  10 81
Baseline mean heart rate (beats/min)
Holter ECG 96.1  13.0 98
12-Lead ECG 99.8  18.5 105
Symptoms
Palpitation 28 (22.4) 10
Shortness of breath 18 (14.4) 8
Dizziness 9 (7.2) 3
Concomitant diseases
Hypertension 91 (72.8) 31
Diabetes mellitus 34 (27.2) 13
Heart failure 18 (14.4) 4
Cardiac diseasesc 40 (32.0) 12
Concomitant drugs
Anticoagulant drugs 112 (89.6) 38
Antiplatelet drugs 27 (21.6) 13
CHADS2 score
d 1.6  1.2 1
ECG, electrocardiogram.
a Mean  standard deviation.
b Number of patients (%).
c Including arrhythmias, valvular diseases, heart failure, cardiomyopathies, or coron
d CHADS2 = 1 point each for congestive heart failure, hypertension, age 75 years, a
* p-Values were calculated using analysis of variance.
y p-Values were calculated using chi-square test.
z p-Values were calculated using Fisher’s exact test.Study design
This multicenter, randomized, double-blind, comparative study
was conducted in 18 medical institutions (see Appendix A) in Japan
between August 2013 and May 2014. Patients were randomly
assigned to 5-mg ﬁxed-dose, 10-mg dose-escalation, or 20-mg
dose-escalation group by a dynamic allocation method adjusted
for baseline 24-h mHR by Holter ECG (Fig. 1).
In each group, during period I, patients started treatment with
carvedilol 5 mg once daily. The necessity of a dose titration was
adjudicated every 2 weeks. In the 10-mg dose-escalation group,
the maximum dose was 10 mg once daily. In the 20-mg dose-
escalation group, the dose was ﬁrst increased to 10 mg and then
to 20 mg once daily. In the 5-mg ﬁxed-dose group, patients
received 5 mg once daily throughout treatment periods I–III. The
criteria for the dose titration were as follows: the dose was
increased when resting HR measured by 12-lead ECG was
>80 bpm and there was no concern regarding patient tolerance
or safety. The dose was not to be increased when the systolic
blood pressure was <110 mmHg. If HR decreased to <60 bpm, the
dose was to be decreased. Carvedilol was discontinued when a
patient met any of the discontinuation criteria (see Supplemen-
tary Table 2).
The study was approved by the institutional review board of
each participating institution, and it was conducted in accordance
with the ethical principles deﬁned in the Helsinki Declaration and
Good Clinical Practice. This study was registered with the Japan
Pharmaceutical Information Center, number JapicCTI-132201.-mg
ose group
10-mg
dose-escalation group
20-mg
dose-escalation group
p-Value
 42 41
.2  9.8 68.1  8.5 69.0  8.9 0.8907*
 (69.0) 29 (69.0) 33 (80.5) 0.4023y
.8  16.1 65.3  13.9 67.9  13.8 0.7341*
.5  4.8 25.4  4.1 25.5  3.8 0.9891*
0.6348y
 (31.0) 12 (28.6) 9 (22.0)
 (69.0) 30 (71.4) 32 (78.0)
 (14.3) 6 (14.3) 5 (12.2) 0.9501y
  14 130  13 130  12 0.8453*
  11 81  9 80  10 0.9138*
.4  15.1 95.6  13.5 94.3  9.8 0.3441*
.7  20.9 98.4  18.8 95.1  14.0 0.0272*
 (23.8) 9 (21.4) 9 (22.0) 0.9629y
 (19.0) 5 (11.9) 5 (12.2) 0.5741y
 (7.1) 1 (2.4) 5 (12.2) 0.1920z
 (73.8) 32 (76.2) 28 (68.3) 0.7096y
 (31.0) 9 (21.4) 12 (29.3) 0.5788y
 (9.5) 9 (21.4) 5 (12.2) 0.2651y
 (28.6) 15 (35.7) 13 (31.7) 0.7808y
 (90.5) 36 (85.7) 38 (92.7) 0.5674y
 (31.0) 7 (16.7) 7 (17.1) 0.1950y
.6  1.2 1.6  1.5 1.7  1.1 0.8715y
ary arterial diseases.
nd diabetes mellitus and 2 points for prior stroke or transient ischemic attack.
Period I Period II Period II I
Trea tment period
Observation period
Within 4 weeks
C
on
se
nt
 o
bt
ai
ne
d
Week  2 Week  4 Week  6Star t of dosing
E
lig
ib
ili
ty
 s
cr
ee
ni
ng
*
R
eg
is
tra
tio
n
R
an
do
m
iz
at
io
n
2 week s 2 week s 2 week s
5 mg QD 10 mg QD 20  mg  QD
5 mg QD 10 mg QD 10  mg QD
5 mg QD 5 mg QD 5 mg QD
Follow-up
period
2 - 4 weeks
20-mg dose-esca lation  group
10-mg dose-esca lation  group
5-mg fixed-dose  group
Fig. 1. Study design. *Including measurements of 24-h mean heart rate on Holter electrocardiogram. QD, once daily.
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Using Holter ECG data (Cardy 303 pico; Suzuken Co., Nagoya,
Japan), the following primary endpoints were evaluated: (1) mHR
at week 2 compared with the baseline value; (2) dose–response
relationship for change in mHR at week 6; (3) change in mHR at
week 4 in 5-mg ﬁxed-dose group compared with that in combined
10-mg and 20-mg dose-escalation group; and (4) change in mHR at
week 6 in 5-mg ﬁxed-dose group compared with that in 20-mg
dose-escalation group. The secondary endpoints were as follows:
(1) percentages of patients whose 24-h mHR or resting HR on 12-
lead ECG achieved 80 bpm or <110 bpm; (2) circadian changes in
the hourly maximum, minimum, and mHR; (3) effect of a dose
increase on mHR in patients who required a dose increase; and (4)
comparison of mHR at week 6 between 10-mg and 20-mg dose-
escalation groups. Other efﬁcacy endpoints included improvement
in symptoms (palpitation, shortness of breath, and dizziness).
The safety endpoints were adverse events (AEs), laboratory
values, blood pressure, and 12-lead ECG ﬁndings.
Statistical analysis
The data are presented as the number (%) of patients and
mean  SD or the mean and 95% conﬁdence interval (CI) unless
otherwise stated. The efﬁcacy analysis was performed for the full
analysis set (FAS), including all patients who took the study drug at
least once and who underwent Holter ECG at least once after
randomization. Sensitivity analysis was performed for the per-
protocol set (PPS) excluding patients from the FAS who violated the
protocol. The missing values were imputed using the last observation
carried forward method. The closed testing procedure was used to
evaluate the four primary endpoints of efﬁcacy. For comparison of HR
between the baseline and week 2, the paired t-test was performed.
Analysis of covariance (using the baseline value as covariate) was
performed to compare the changes in HR from baseline between the
ﬁxed-dose group and the dose-escalation group, as well as to evaluate
the dose–response relationship by linear contrast (1, 0, 1), and to
compare the secondary endpoints between groups (the changes in HR
from baseline are shown as the least square mean and 95% CI). Fisher’s
exact test was used to compare proportions of patients who achieved
target HR. McNemar test was used to compare prevalence rates of
symptoms. The safety analysis population included randomized
patients who had received the study drug at least once.
Using the changes in HR (mean  SD) in the 5-mg ﬁxed-dose
group and the combined 10-mg and 20-mg dose-escalation group
reported in the previous study [9], we calculated the numbers ofpatients necessary to detect a signiﬁcant difference between the
groups with a power of 80%. Allowing potential dropouts, the sample
size for each group was determined to be 40 patients.
Statistical analyses were carried out using SAS System Release
9.2 (SAS Institute, Cary, NC, USA) with a signiﬁcance level of 5%
(two sided).
Results
Patients
A total of 127 patients were enrolled in the present study
(Fig. 2). Of these, four patients discontinued the treatment, and
one patient could not visit hospital periodically. Consequently,
122 patients completed the study. Of 124 patients with
judgments of dose titration at weeks 2 and 4, 26 patients
(21.0%) did not require a dose increase from 5 mg to 10 mg, while
98 patients (79.0%) required a dose increase (Fig. 3). Of 53 patients
who received 10 mg during period II, 15 patients (28.3%) did not
require a dose increase to 20 mg, while 38 patients (71.7%) did so.
No patient required a dose reduction at either week 2 or week 4,
in any of the treatment groups. There were four patients whose
length of ECG recording did not reach 24 h. However, all patients
had ECG recorded for at least 23 h, and there was no missing
value.
The baseline characteristics of patients are shown in Table 1.
Supplementary Table 3 shows baseline 24-h mHR. There were no
differences in the baseline characteristics among treatment groups
except for baseline mHR on 12-lead ECG (p = 0.0272).
Efﬁcacy
HR reduction assessed by Holter ECG
After 2 weeks, 24-h mHR decreased from baseline in all three
groups (Fig. 4). In the 5-mg ﬁxed-dose group, HR reduction was
maintained from week 2 to week 6 at the same level, whereas in
the 10-mg dose-escalation group, HR continued to decrease until
week 4 and thereafter was maintained at the same level until week
6. In the 20-mg dose-escalation group, HR reduction continued
until week 6. Resting HR also showed a similar reduction, although
the values varied compared with 24-h mHR (data not shown).
Primary endpoints
HR reduction by 5 mg. Among all the patients who took 5 mg
(combining patients in all groups), 24-h mHR at week 2 was
20-mg dose -
escalation  group 
n = 43
Patients providing
informed consen t
n = 162
Screen  failure  during 
observation period,  n = 35
10-mg dose -
escalation  group 
n = 42
5-mg fixed-dose 
group
n = 42
Completed
treatment
n = 40
Completed
treatment
n = 41
Completed
treatment
n = 42
Completed trial
n = 40
Completed trial
n = 41
Completed trial
n = 41
Discontinu ed due 
to patient  request
n = 1
Discontinu ed due  to
AEs, n = 2 (no  data 
after treatment).
Met discontinuati on 
criteria*,  n = 1
Discontinu ed 
during follow-u p
due to  SAE,  n = 1.
Randomized
n = 127
Assessed  wi th FAS 
excluding patients
with no da ta, n = 41
Assessed  with  FAS
n = 42
Assessed  with  FAS
n = 42
Fig. 2. Patient disposition. FAS, full analysis set; AE, adverse event; SAE, severe adverse event. *Discontinuation criteria: systolic blood pressure <100 mmHg or diastolic blood
pressure <60 mmHg.
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(p < 0.0001) (Fig. 5a). The change from baseline in resting HR was
9.7 (7.3–12.1) bpm (p < 0.0001).
Dose–response relationship in HR reduction. The least square means
of the change in 24-h mHR at week 6 were 7.6 (5.4–9.8) in the 5-mgTreatment 
group
Period I 
71.4% (30/42)
28.6% (12/42)
5-mg
fixed-dose
group
5 mg
(n = 42)
Required a dose  escalatio n
No dose  escalation  required  
10-mg
dose-escalation
group
5 mg
(n = 42)
64.3% (27/42)
35.7% (15/42)
5 mg
(n = 43)
65.0% (26/40)
35.0% (14/40)
20-mg
dose-escalation
group
Fig. 3. Number of patients who required dose escalation at each period and number of
(upper), the 10-mg dose-escalation group (middle), and the 20-mg dose-escalation groﬁxed-dose group, 8.9 (6.7–11.1) in the 10-mg dose-escalation
group, and 10.6 (8.4–12.8) bpm in the 20-mg dose-escalation
group (p = 0.0638 for trend) (Fig. 5b). In contrast to the results in
FAS, the analysis in PPS showed a signiﬁcant dose–response
relation for HR reduction (p = 0.0364 for trend). The changes in the
resting HR showed a similar trend with those in 24-h mHR (Fig. 5c),Period II Period II I
80.0%  (24/30)
20.0%  (6/30)
41.7%  (5/12)
58.3%  (7/12)
5 mg
71.4%  (30 /42)
5 mg
28.6%  (12 /42)
5 mg
11.9%  (5/42)
5 mg
16.7%  (7/42)
5 mg
14.3%  (6/42)
5 mg
57.1%  (24 /42)
10 mg
64.3%  (27 /42)
5 mg
35.7%  (15 /42)
10 mg
21.4%  (9/42)
10 mg
42.9%  (18 /42)66.7%  (18/27)
10 mg
16.7%  (7/42)
33.3%  (9/27)
46.7%  (7/15)
53.3%  (8/15)
5 mg
19.0%  (8/42)
10 mg
65.0%  (26 /40)
5mg
35.0%  (14 /40)
10 mg
15.0%  (6/40)
20 mg
50.0%  (20 /40)76.9%  (20/26)
10 mg
7.5%  (3/40)
5 mg
27.5%  (11 /40)
23.1%  (6/26)
21.4%  (3/14)
78.6%  (11/14)
 patients who were actually treated with each dose in the 5-mg ﬁxed-dose group
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Fig. 5. Changes in heart rate from baseline to week 2 by Holter electrocardiogram (ECG) in
to week 6 by Holter ECG (b) and 12-lead ECG (c) in each dose group; from baseline t
(combining 10 mg and 20 mg groups) (d). Each column and bar represent the least squa
minute. *p < 0.0001 (paired t-test versus baseline); yp = 0.0638 for trend (analysis of covar
baseline level as a covariate).
Fig. 4. Changes in 24-h mean heart rate on Holter electrocardiogam monitoring.
Each symbol and bar represent the arithmetic mean and standard deviation,
respectively (full analysis set using the last observation carried forward method).
*p < 0.0001 (versus pre-treatment value; paired t-test).
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for trend).
Effects of a dose-increase regimen to 10 mg on HR reduction. The
least square mean of change in 24-h mHR from baseline at week
4 was 6.3 (3.8–8.7) bpm in the 5-mg ﬁxed-dose group compared
with 8.6 (6.9–10.4) bpm in the dose-escalation groups (combining
the 10 mg and 20 mg groups). Although the difference was not
signiﬁcant [2.4 (0.64 to 5.37) bpm, p = 0.1224], the point
estimation of the reduction in HR was greater in the dose-
escalation groups than in the ﬁxed-dose group (Fig. 5d).
Effects of a dose-increase regimen to 20 mg on HR reduction. The
change in 24-h mHR from baseline at week 6 was 7.7 (5.7–9.7) in
the 5-mg ﬁxed-dose group, compared with 10.7 (8.6–12.7) bpm in
the 20-mg dose-escalation group with a signiﬁcantly greater
reduction [2.9 (0.06–5.80) bpm, p = 0.0453] .
Secondary endpoints
Proportion of patients who achieved target HR. The proportion of
patients who achieved the target 24-h mHR 80 bpm at least onceg
dose
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dose-escalation
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Fig. 6. Changes in hourly arithmetic mean (a), and minimum and maximum (b) heart rate by 24-h Holter electrocardiogram monitoring. Each symbol and bar represent the
arithmetic mean and standard deviation, respectively (full analysis set not using the last observation carried forward method). HR, heart rate. *from uprising to bedtime;
**from bedtime to uprising. ***comparison between daytime versus nighttime in terms of the changes in HR from baseline by paired t-test.
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dose group, 38.1% (16/42) in the 10-mg dose-escalation group, and
46.3% (19/41) in the 20-mg dose-escalation group (p = 0.3788,
Fisher’s exact test). The proportion of patients with baseline mHR
110 bpm who achieved <110 bpm at least once during treatment
was 57.1% (4/7 patients) in the 5-mg ﬁxed-dose group, 66.7% (4/6)
in the 10-mg dose-escalation group, and 100.0% (4/4) in the 20-mg
dose-escalation group (p = 0.3462, Fisher’s exact test).
Circadian change in hourly maximum, minimum, and mHR. Fig. 6
shows the circadian changes in the hourly mean (Fig. 6a), and
maximum and minimum HR (Fig. 6b) in each dose group at week
6 compared with the baseline values, which were combined for alldose groups (see Supplementary Fig. 1 for the circadian changes in
the relevant values at weeks 2, 4, and 6). In all dose groups, a
decrease in HR was greater during the daytime compared with the
value during the night.
Effects of dose escalation to 10 mg or 20 mg on circadian
changes in hourly mHR are shown in Fig. 7. The circadian changes
in hourly mHR in the patients without dose escalation over-
lapped with the baseline values. In contrast, the changes in
patients with dose escalation to 10 mg or 20 mg deviated from
both the baseline values at 5 mg or 10 mg and the values in
patients without dose escalation, indicating that there was an
additional and relevant decrease in HR especially during the
daytime.
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Fig. 7. Changes in heart rate by 24-h Holter electrocardiogram monitoring. Panel a, patients required dose escalation of carvedilol from 5 mg to 10 mg; Panel b, from 10 mg to
20 mg (full analysis set not using the last observation carried forward method).
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Prevalence rates of palpitation at baseline and week 6 were
22.4% and 19.2% (p = 0.1655, McNemar test), respectively. Those of
shortness of breath at baseline and week 6 were 14.4% and 12.0%
(p = 0.2568, McNemar test), and those of dizziness were 7.2% and
5.6% (p = 0.3173, McNemar test), respectively. There was no
signiﬁcant difference in the prevalence rates at baseline and week
6 among all groups.
Safety
Blood pressure
Throughout the observation and treatment periods, there was
no relevant change in blood pressure in all dose groups
(Supplementary Fig. 2).
Adverse events
The incidence of adverse events (AEs) among all the patients
was 47.2%, and did not differ among the three groups. Of those AEs,7.9% (10/127 patients) had a potential causal relationship with the
study drug. No death or serious AE related to the study drug
occurred. AEs leading to study discontinuation occurred in two
patients of the 20-mg dose-escalation group, i.e. worsening of
chronic heart failure during 5 mg treatment. The symptoms
improved after discontinuation of the study drug and treatment
with appropriate medication. There were some patients who had
R–R interval 3 s (three patients during the observation period; six
patients at week 2; six patients at week 4; and ﬁve patients at week
6). However, there was no dose–response relationship observed in
the maximum R–R interval among the three dosage-regimen
groups.
Discussion
The major ﬁndings of the present study were as follows. First,
carvedilol 5 mg signiﬁcantly reduced 24-h mHR on Holter ECG.
Second, a signiﬁcantly greater HR reduction at week 6 was
observed in the 20-mg dose-escalation group compared with the
H. Inoue et al. / Journal of Cardiology 69 (2017) 293–3013005-mg ﬁxed-dose group. Third, in patients with insufﬁcient HR
reduction by 5 mg or 10 mg, a further reduction can be expected by
a dose increase to 10 mg or 20 mg, respectively.
Carvedilol blocks not only both b1 and b2 receptors but also a1
receptor, and is unlikely to cause excessive bradycardia. In this
study, as expected from the result of a previous study [10],
carvedilol decreased HR in a dose-dependent manner during the
daytime when HR is elevated because of an increase in sympathetic
tone. However, it did not extensively decrease HR during the night
when the HR is relatively low due to an increase in parasympa-
thetic tone even when the dose was increased. Moreover, HR
increase was suppressed in the early morning of the following day
when HR started to rise. Therefore, persistent 24-h HR control
effect of carvedilol once daily was conﬁrmed. Furthermore, the
maximum HR was suppressed greater than the minimum HR, a
ﬁnding consistent with the previous result [9], suggesting that
carvedilol is less likely to cause excessive HR reduction leading to
bradycardia.
The proportion of patients who achieved mHR 80 bpm, as
measured by Holter ECG and 12-lead ECG, increased along with an
increase in the maximum given dose. Furthermore, in the 20-mg
dose-escalation group, all patients with baseline mHR 110 bpm
achieved <110 bpm on both Holter ECG and 12-lead ECG at least
once after the treatment. The guidelines in Japan also recommend
that physicians should consider starting with a lenient target for
resting HR (<110 bpm) with the aim to improve subjective
symptoms [5] based on the results of RACE II study [11]. The
present study showed that carvedilol 5–20 mg is sufﬁciently
effective for the initial treatment for patients with HR 110 bpm.
In the present study, 19% of patients (8/42) in the 10-mg dose-
escalation group took 5 mg, and 50% of patients (20/40) in the 20-
mg dose-escalation group took 10 mg (Fig. 3), showing that some
patients required dose adjustment. The aim of the present study
was to evaluate the relation between doses used in clinical practice
and their efﬁcacy, so we conﬁrmed that appropriate doses vary
between individual patients. Based on this ﬁnding, we consider
that the dose should be started with 5 mg and be increased to
10 mg/20 mg if the efﬁcacy is insufﬁcient.
There was no substantial difference in the safety proﬁle of
carvedilol from that reported previously [12–16] in patients with
hypertension, angina pectoris, or chronic heart failure, and thus
there was no safety concern speciﬁc to patients with AF. However,
two patients with concomitant heart failure of NYHA class I
showed worsening of chronic heart failure (mild and moderate
severity) during 5-mg treatment. Therefore, in the treatment of
tachycardiac AF patients with chronic heart failure, carvedilol
should be administered cautiously in accordance with the dosage
and administration for the treatment of heart failure.
Other than carvedilol, b-blockers frequently used for HR control
are bisoprolol and atenolol in Japan. Bisoprolol is approved for
treatment of tachycardiac AF, and has a potent HR-decreasing
effect in patients with chronic AF [10]. In patients with AF,
carvedilol 5 mg may have a relatively mild effect [the change in
mHR from baseline was 6.6 bpm (95% CI: 5.2–8.0) in the present
study] compared to the starting dose of 2.5 mg of bisoprolol (the
change in mHR from baseline is 12.2  9.1 bpm [10]). However,
carvedilol provided sufﬁcient efﬁcacy to achieve a target HR of
<110 bpm by the initial treatment, and that of <80 bpm in patients
who need further HR reduction by dose escalation, with a favorable
safety proﬁle.
The present study had the following limitations. Firstly, the
sample size was small (127 patients). Therefore, the statistical
power was not robust. Secondly, the treatment period was short
(6 weeks), and long-term effects of carvedilol on HR were not clear.
A further outcome study involving a large number of patients with
a longer study period will be required. Thirdly, a placebo arm wasnot employed due to ethical issues. Fourthly, the dose-escalation
groups included some patients for whom a dose increase was not
considered necessary and they received the same dose continu-
ously, and thus the HR reduction may be underestimated in the
primary endpoints. Finally, standard qualify-of-life scores for AF
were not used in the present study. Therefore, effects of carvedilol
on quality of life were not determined quantitatively.
Although limited for these reasons, the present study indicated
that carvedilol is effective for dose-dependently reducing HR in
patients with AF tachycardia.
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